SCHEMBL10075725

SCHEMBL10075725

CC(=O)O/N=C(\C)C(=O)c1cccc(Sc2ccc(C(=O)OCCO)cc2)c1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.38
L3MBTL1 Q9Y468 4/20 0.36
KMT2A Q03164 1/20 0.36
ALDH1A1 P00352 4/20 0.35
HPGD P15428 2/20 0.35
LMNA P02545 3/20 0.34
TDP1 Q9NUW8 4/20 0.33
CA1 P00915 2/20 0.32
CA2 P00918 2/20 0.32
KDM4E B2RXH2 1/20 0.32
GAA P10253 1/20 0.32
CYP4F2 P78329 1/20 0.31
CYP4A11 Q02928 1/20 0.31
POLB P06746 1/20 0.31
MAPT P10636 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
TSHR P16473 2/20 0.31
ESR1 P03372 1/20 0.31
CHRM1 P11229 1/20 0.31
SLC6A2 P23975 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10075722 0.96 SLC7A5 (0.40) SLC7A5L3MBTL1KMT2AALDH1A1HPGD
SCHEMBL10075709 0.90 L3MBTL1 (0.43) SLC7A5L3MBTL1KMT2AALDH1A1HPGD
SCHEMBL20709809 0.87 SLC7A5 (0.38) SLC7A5L3MBTL1KMT2AALDH1A1HPGD
SCHEMBL10075747 0.86 GAA (0.40) L3MBTL1KMT2AALDH1A1HPGDLMNA
SCHEMBL10075719 0.85 L3MBTL1 (0.36) SLC7A5L3MBTL1KMT2AALDH1A1HPGD
SCHEMBL10075753 0.84 L3MBTL1 (0.43) L3MBTL1KMT2AALDH1A1HPGDLMNA
SCHEMBL10075804 0.84 L3MBTL1 (0.43) L3MBTL1KMT2AALDH1A1HPGDLMNA
SCHEMBL10075718 0.83 MAPT (0.35) SLC7A5L3MBTL1KMT2AALDH1A1HPGD
SCHEMBL10075717 0.83 HPGD (0.33) SLC7A5L3MBTL1KMT2AHPGDLMNA
SCHEMBL10075785 0.83 APEX1 (0.39) SLC7A5L3MBTL1KMT2AALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2586827-B1 CURABLE RESIN COMPOSITION ADEKA CORP (JP) 2017-12-27 EP disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
US-8735511-B2 Curing resin composition ADEKA CORPORATION (JP) 2014-05-27 US disclosed
EP-2586827-A1 CURABLE RESIN COMPOSITION Adeka Corporation (JP) 2013-05-01 EP disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-20120115972-A1 CURING RESIN COMPOSITION ADEKA CORPORATION (JP) 2012-05-10 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
US-8148045-B2 Oxime ester compound and photopolymerization initiator containing the same ADEKA CORPORATION (JP) 2012-04-03 US disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME ADEKA CORPORATION (JP) 2011-06-02 US disclosed
EP-2327689-A1 Oxime ester compound and photopolymerization initiator containing the same Adeka Corporation (JP) 2011-06-01 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110129778-A1 OXIME ESTER COMPOUND AND PHOTOPOLYMERIZATION INITIATOR CONTAINING THE SAME OXER1, OR10J3, CDK11B SLC7A5 1844/4885L3MBTL1 1628/4885KMT2A 3531/4885
US-20120115972-A1 CURING RESIN COMPOSITION LTA, LOXL1, PLOD2 SLC7A5 3079/4885L3MBTL1 228/4885KMT2A 247/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.